drug
ceritinib
Marketedupdated 3mo agoby $NVS NOVARTIS AG
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2indications
investigational
NSCLC
all catalysts(1)
Trials studying ceritinib
- phase1Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer
- phase4Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
- —Managed Access Programs for LDK378, Ceritinib
- phase1Next Generation Personalized Neuroblastoma Therapy
- phase1Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma
- phase2Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- —A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
- phase3LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 20, 2027
~1.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (15)
- Dec 13, 2037method-of-use (U-3096)US 12357630
- Feb 2, 2032method-of-use (U-1179)US 8703787
- Feb 2, 2032method-of-use (U-1179)US 8703787
- Jan 18, 2032compositionUS 9309229
- Jan 18, 2032compositionUS 9309229
- Jun 29, 2030compositionUS 80394793.9y
- Jun 29, 2030compositionUS 80394793.9y
- Apr 29, 2028compositionUS 79645921.7y
- Apr 29, 2028compositionUS 79645921.7y
- Nov 20, 2027method-of-use (U-1179)US 83779211.3y
- Nov 20, 2027method-of-use (U-1179)US 83779211.3y
- Nov 20, 2027compositionUS 83994501.3y
- Nov 20, 2027compositionUS 83994501.3y
- Apr 25, 2026compositionUS 7893074
- Apr 25, 2026compositionUS 7893074
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 15m ago
Found something off?
comments(0)
5-min edit window · permanent after that